infertility
Conditions
Interventions
Experimental group:In the hormone replacement therapy-frozen embryo transfer (HRT-FET) protocol, domestic estradiol valerate tablets are used as estrogen supplementation.
Control group:In the hormone replacement therapy frozen-thawed embryo transfer (HRT-FET) protocol, imported estradiol valerate tablets are used as estrogen supplementation
Sponsors
Sichuan Provincial Women and Children's Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing HRT-FET at the Reproductive Medicine Center of Sichuan Provincial Women and Children’s Hospital; 2. Aged 20-40 years; 3. Transferring blastocysts; 4. Voluntarily participating in the study and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. FET using embryos derived from frozen eggs or sperm; 2. Preimplantation genetic testing (PGT) cycles; 3. Factors affecting embryo implantation, such as submucosal or intramural fibroids, adenomyosis, intrauterine adhesions, uterine malformations, or thin endometrium; 4. Severe chronic diseases of the cardiovascular, respiratory, or digestive systems, or serious endocrine or autoimmune diseases such as diabetes or systemic lupus erythematosus; 5. Participation in other drug or device clinical trials within the 3 months prior to treatment, and use of investigational drugs or devices; 6. Allergy to estradiol valerate; 7. Body mass index (BMI) =28 (obese); 8. Other medical conditions that the investigator deems may affect the assessment of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sex hormone levels;Ultrasound assessment indicators of endometrial receptivity;Embryo implantation rate;Spontaneous abortion rate;Ectopic pregnancy rate;Ongoing pregnancy rate;Live birth rate; | — |
Countries
China
Contacts
Public ContactGong Yan
Sichuan Provincial Women’s and Children’s Hospital
Outcome results
None listed